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Abstract
Background: NADPH oxidase (NOX2) is an enzyme system that generates reactive oxygen species (ROS) in
microglia and macrophages. Excessive ROS production is linked with neuroinflammation and chronic
neurodegeneration following traumatic brain injury (TBI). Redox signaling regulates macrophage/microglial
phenotypic responses (pro-inflammatory versus anti-inflammatory), and NOX2 inhibition following moderate-to-
severe TBI markedly reduces pro-inflammatory activation of macrophages/microglia resulting in concomitant
increases in anti-inflammatory responses. Here, we report the signaling pathways that regulate NOX2-dependent
macrophage/microglial phenotype switching in the TBI brain.
Methods: Bone marrow-derived macrophages (BMDMs) prepared from wildtype (C57Bl/6) and NOX2 deficient
(NOX2−/−) mice were treated with lipopolysaccharide (LPS; 10 ng/ml), interleukin-4 (IL-4; 10 ng/ml), or combined
LPS/IL-4 to investigate signal transduction pathways associated with macrophage activation using western
immunoblotting and qPCR analyses. Signaling pathways and activation markers were evaluated in ipsilateral cortical
tissue obtained from adult male wildtype and NOX2−/− mice that received moderate-level controlled cortical
impact (CCI). A neutralizing anti-IL-10 approach was used to determine the effects of IL-10 on NOX2-dependent
transitions from pro- to anti-inflammatory activation states.
Results: Using an LPS/IL-4-stimulated BMDM model that mimics the mixed pro- and anti-inflammatory responses
observed in the injured cortex, we show that NOX2−/− significantly reduces STAT1 signaling and markers of pro-
inflammatory activation. In addition, NOX2−/− BMDMs significantly increase anti-inflammatory marker expression;
IL-10-mediated STAT3 signaling, but not STAT6 signaling, appears to be critical in regulating this anti-inflammatory
response. Following moderate-level CCI, IL-10 is significantly increased in microglia/macrophages in the injured
cortex of NOX2−/− mice. These changes are associated with increased STAT3 activation, but not STAT6 activation,
and a robust anti-inflammatory response. Neutralization of IL-10 in NOX2−/− BMDMs or CCI mice blocks STAT3
activation and the anti-inflammatory response, thereby demonstrating a critical role for IL-10 in regulating
NOX2-dependent transitions between pro- and anti-inflammatory activation states.
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Conclusions: These studies indicate that following TBI NOX2 inhibition promotes a robust anti-inflammatory
response in macrophages/microglia that is mediated by the IL-10/STAT3 signaling pathway. Thus, therapeutic
interventions that inhibit macrophage/microglial NOX2 activity may improve TBI outcomes by not only
limiting pro-inflammatory neurotoxic responses, but also enhancing IL-10-mediated anti-inflammatory
responses that are neuroprotective.
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Background
Macrophages play a critical role in regulating the innate
immune response to acute and chronic inflammation,
and they can change their activation state in response to
growth factors and external cues [1]. In the central
nervous system (CNS) following traumatic brain injury
(TBI), resident microglia and infiltrating macrophages
respond to the local injury; depending upon their
activation state, they may contribute either to secondary
injury or neurorestoration [2]. Macrophages exhibit a
diverse array of activation phenotypes, each with
different physiological and functional roles [1, 3, 4]. In
vitro studies have demonstrated that pro-inflammatory
(M1-like) activation is characterized by upregulation of
inflammatory mediators such as nitric oxide synthase
(NOS2) and pro-inflammatory cytokines (tumor necrosis
factor α (TNFα), interleukin-1β (IL-1β)) and is associ-
ated with production of reactive oxygen species (ROS)
[1]. It can be induced by the pro-inflammatory cytokine
interferon (IFN)-γ and activation of toll-like receptors
(TLR). IFN-γ stimulation leads to phosphorylation of
the transcription factor signal transducer activator of
transcription (STAT)1, and effects of the TLR4 agonist,
lipopolysaccharide (LPS), are mediated, in part, through
STAT1 [5]. In contrast, anti-inflammatory (M2-like)
macrophages are involved in both wound healing and
resolution of inflammatory responses [4]. They are
marked by expression of factors such as mannose recep-
tor (CD206), arginase-1 (Arg1), and chitinase 3-like 3
(YM1). Stimulation of macrophages with interleukin-4
(IL-4) upregulates the expression of markers of the
anti-inflammatory phenotype—effects mediated in part
through activation of STAT6 [6]. Other inflammatory
mediators such as interleukin-10 (IL-10) [7] and insulin-
stimulating growth factor-1 (IGF-1) [8] may also activate
the anti-inflammatory phenotype.
Defining specific activation states in vivo is challenging
due to the diversity of phenotypes, which are dependent
on environmental and tissue-specific cues that allow
microglia/macrophages to perform specific functions
under different physiological and pathological condi-
tions. The in vitro-defined phenotypic classification
system (M1 versus M2 polarization) oversimplifies the
activation spectrum that exists in humans and animal
models [9] and does not describe the actual diversity of
microglial/macrophage reactive states. This has led to
serious questioning of the use of M1/M2 classification in
microglia [10] and peripheral macrophages [11]. The
actual mechanisms underlying phenotypic changes in
microglia/macrophages are not fully elucidated, and an
accepted nomenclature that describes such complex
cellular responses is currently lacking. It has been
demonstrated that the microglial/macrophage activation
response to TBI is highly complex, with individual
cells concurrently expressing both pro- and anti-
inflammatory phenotype markers in unique profiles that
can be altered as a function of time, injury localization,
and injury severity [12–14]. In the current study, we use
general terms, pro-inflammatory, and anti-inflammatory,
to describe microglial/macrophage phenotypic responses
in the TBI brain.
NADPH oxidase (NOX2) is a multi-subunit enzyme
complex responsible for the production of both intracel-
lular and extracellular ROS by phagocytes, including
microglia and macrophages [15]. NOX2 is the primary
source of ROS generation in macrophages [16], and it
participates in a wide range of cellular processes,
including host defense, cell signaling, and cell differenti-
ation. Excessive NOX2 activation is implicated in the
progression of a number of neurodegenerative disorders
[17–19]. Following a moderate-to-severe TBI NOX2 is
chronically elevated in reactive macrophages/microglia
surrounding the lesion for weeks to months post-
injury [20, 21]. NOX2 expression is also markedly
increased in aged animals after TBI and is associated
with increased pro-inflammatory activation and suppressed
anti-inflammatory marker expression [22]. Notably, NOX2
inhibition reduces markers of pro-inflammatory activation,
limits tissue loss and neurodegeneration, and improves
neurological recovery in TBI mice [12, 23–26]. NOX2
inhibition also results in enhanced expression of anti-
inflammatory markers in macrophage/microglia [24, 27],
and infiltrating macrophages are major contributors to the
anti-inflammatory environment in the TBI brain in NOX2
knockout mice [24]. Based on accumulating pre-clinical
evidence supporting NOX2-mediated neuroinflammation
as an important therapeutic target for TBI, the goal
of the current study was to elucidate the cell
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signaling mechanisms that regulate NOX2-dependent




Studies were performed using either NOX2-deficient
(NOX2−/−; B6.129S-Cybbtm1Din/J, stock 002365; Jackson
Laboratories, Bar Harbor, ME,) adult male mice (10–
12 weeks old), or age-matched C57Bl/6 J (WT) male
mice. Mice were housed in the Animal Care facility at
the University of Maryland School of Medicine under a
12 h light–dark cycle, with ad libitum access to food and
water. All surgical procedures were carried out in
accordance with protocols approved by the Institutional
Animal Care and Use Committee (IACUC) at the
University of Maryland School of Medicine.
Controlled cortical impact
Our custom-designed controlled cortical impact (CCI)
injury device consists of a microprocessor-controlled
pneumatic impactor with a 3.5-mm diameter tip as
previously described [28]. Briefly, mice were anesthetized
with isoflurane evaporated in a gas mixture containing
70% N2O and 30% O2 and administered through a nose
mask. Mice were placed on a heated pad, and core body
temperature was maintained at 37 °C. The head was
mounted in a stereotaxic frame, a 10-mm midline inci-
sion was made over the skull, and the skin and fascia
were reflected. A 5-mm craniotomy was made on the
central aspect of the left parietal bone. The impounder
tip of the injury device was then extended to its full
stroke distance (44 mm), positioned to the surface of the
exposed dura, and reset to impact the cortical surface.
Moderate-level CCI was induced using an impactor
velocity of 6 m/s and deformation depth of 2 mm. After
injury, the incision was closed with interrupted 6–0 silk
sutures, anesthesia was terminated, and the animal was
placed into a heated cage to maintain normal core
temperature for 45 min post-injury. Sham animals
underwent the same procedure as CCI mice except for
the impact.
Intracerebroventricular (i.c.v.) guide cannula implantation
and osmotic pump infusion
Prior to CCI, the right lateral ventricle of the mouse was
stereotaxically perforated with a brain infusion kit 3
(ALZET, DURET Corporation, Cupertino, CA, USA;
coordinates: 0.7 mm posterior to the bregma, 1.5 mm
lateral to the bregma, 2 mm deep). Immediately follow-
ing CCI on the left parietal cortex the infusion cannula
was connected to an osmotic minipump (ALZET; pump
model: 1007D) that was implanted subcutaneously (sc)
in the animal’s back, just behind scapula. Osmotic
pumps were primed for approximately 8 h prior to
implantation and were either filled with 1 mg/ml anti-
IL-10 neutralizing antibody (αIL-10; clone JES5-16E3;
eBioscience, San Diego, CA) or equal concentration
isotype control rat αIgG2b K (clone Eb149/10h5
eBioscience). Once implanted, the pumps continually
infused αIL-10 or control αIgG2b K into the lateral
ventricle for 3 days at a rate of 0.5 μL/h.
Study 1
Sham (n = 5) and CCI (n = 5) of WT and NOX2−/− mice
were anesthetized (100 mg/kg sodium pentobarbital,
I.P.) at 1, 3, and 7 days post-injury and transcardially
perfused with ice-cold 0.9% saline (100 ml). Ipsilateral
cortical tissue was rapidly dissected and was snap-frozen
on liquid nitrogen for RNA extraction.
Study 2
Sham (n = 5) and CCI (n = 5) of WT and NOX2−/− mice
were anesthetized (100 mg/kg sodium pentobarbital,
I.P.) at 7 days post-injury and transcardially perfused
with ice-cold 0.9% saline (100 ml), followed by 300 ml of
4% paraformaldehyde. Brains were removed and post-
fixed in 4% paraformaldehyde overnight and were
cryoprotected in 30% sucrose for histological analysis.
Study 3
αIL-10 (1 mg/ml) or isotype control αIgG2b K was
delivered i.c.v. via osmotic pump infusion to WT and
NOX2−/− CCI mice (n = 6/group). The dose of αIL-10
was chosen based on prior studies demonstrating
neutralization of IL-10 in a mouse model of spinal cord
injury (SCI) [29]. Sham WT mice (n = 6) were used as
control for baseline mRNA expression levels. Animals
were anesthetized (100 mg/kg sodium pentobarbital,
I.P.) at 3 days post-injury and transcardially perfused
with ice-cold 0.9% saline (100 ml). Ipsilateral cortical
tissue was rapidly dissected and was snap-frozen on
liquid nitrogen for RNA extraction.
Preparation and culture of bone marrow-derived macro-
phages (BMDMs)
BMDMs were isolated from the marrow of the femurs
and tibias of uninjured adult WT and NOX2−/− male
mice as previously described [8]. Briefly, following ter-
minal anesthesia (100 mg/kg sodium pentobarbital, I.P.),
the marrow was flushed out into a sterile falcon tube in
Dulbecco’s modified Eagle’s medium (DMEM; Gibco
Invitrogen, Carlsbad, CA) supplemented with heat-
inactivated fetal bovine serum (FBS; 10%; Atlanta Biolog-
icals, Flowery Branch, GA) and penicillin/streptomycin
(1%; Gibco Invitrogen) to obtain a single cell suspension.
The suspension was centrifuged (400 × g, 5 min), the
supernatant was discarded, and the resulting pellet was
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resuspended in 20 ml of DMEM supplemented with
Ladmac-conditioned media (20%). Cells were seeded in
sterile cell culture flasks (T75 cm2 flasks) and were
maintained in culture for a further 6 days, with media
being replaced on day 4. On day 6, cells were transferred
to 24-well plates (0.4 × 106 cells per well) or 96-well
plates (0.5 × 105 cells per well) and remained in culture
for a further 2 days.
Treatment of BMDMs
Cells were incubated in the presence of both LPS
(10 ng/ml; Sigma-Alrich, St. Louis, MO) and IL-4
(10 ng/ml; R&D Systems, Minneapolis, MN), superna-
tants were collected for analysis of cytokines by ELISA,
and cells were harvested for analysis of markers of
macrophage activation by real-time PCR and polyacryl-
amide gel electrophoresis followed by western immuno-
blotting. To investigate IL-10-mediated effects in anti-
inflammatory activation, cells were treated with LPS/IL-
4 in the presence or absence of a neutralizing antibody
to αIL-10 (10 μg/ml; eBioscience) or the appropriate iso-
type control (rat αIgG2b K; eBioscience).
Real-time PCR
Total RNA was extracted from BMDMs and snap-frozen
sham and TBI cortical tissue of WT and NOX2−/− mice
using an RNeasy isolation kit (Qiagen, Valencia, CA)
with on-column DNase treatment (Qiagen). cDNA syn-
thesis was performed using a Verso cDNA RT kit
(Thermo Scientific, Pittsburg, PA); the protocols used
were according to the manufacturer’s instructions. Real-
time PCR was performed using TaqMan gene expression
assays (Ym1, Mm00657889_m1; Arg1, Mm00475988_m1;
SOCS3, Mm00545913_s1; IL-4Rα, Mm00446186_m1;
TGF-β, Mm00441724_m1; SHIP1, Mm00494987_m1; and
GAPDH Mm99999915_g1; Applied Biosystems, Carlsbad,
CA) on an ABI 7900 HT FAST Real-Time PCR machine
(Applied Biosystems). Samples were assayed in duplicate
in one run (40 cycles), which was composed of 3 stages,
50 °C for 2 min, 95 °C for 10 s for each cycle (denatur-
ation) and finally the transcription step at 60 °C for 1 min.
Gene expression was calculated relative to the endogenous
control sample (GAPDH) to determine relative expression
values, using the 2 −ΔΔCt method (where Ct is the
threshold cycle).
Western blotting
Proteins from BMDMs and ipsilateral cortical tissue
were extracted using RIPA buffer, equalized, and loaded
onto 5–20% gradient gels for SDS PAGE (Bio-Rad;
Hercules, CA). Proteins were transferred onto nitro-
cellulose membranes and then blocked for 1 h in 5%
milk in 1 × TBS containing 0.05% Tween-20 (TBS-T) at
room temperature. The membrane was incubated in
mouse anti-arginase 1 (N-20) (1:1000; BD Transduction
Laboratories, San Jose, CA), rabbit anti-STAT6 (1:1000;
Cell signaling, Danvers, MA), rabbit anti-pSTAT6
(1:1000; Cell signaling), mouse anti-STAT3 (1:1000; Cell
signaling), rabbit anti-pSTAT3 (1:1000; Cell signaling),
or mouse anti-β-Actin (1:5000; Sigma-Aldrich) overnight
at 4 °C, then washed three times in TBS-T, and incu-
bated in appropriate HRP-conjugated secondary anti-
bodies (Jackson ImmunoResearch Laboratories, West
Grove, PA) for 2 h at room temperature. Membranes
were washed three times in TBS-T, and proteins were vi-
sualized using SuperSignal West Dura Extended Dur-
ation Substrate (Thermo Scientific, Rockford, IL).
Chemiluminescence was captured ChemiDoc™ XRS+
System (Bio-Rad), and protein bands were quantified by
densitometric analysis using BioRad Molecular Imaging
Software. The data presented reflects the intensity of tar-
get protein band normalized based on the intensity of
the endogenous control for each sample (expressed in
arbitrary units).
Cytokine and nitric oxide analysis
Concentrations of TNFα (R&D Systems; DY410), IL-6
(R&D Systems; DY406), and IL-10 (R&D Systems;
DY41705) were measured in supernatant samples ob-
tained from BMDMs by ELISA. Briefly, standards or
samples (100 μl) were added to antibody-coated 96-
well plates and incubated for 2 h at room
temperature, plates were washed and samples were
incubated in detection antibody for 2 h. Plates were
washed and incubated in horseradish peroxidase-
conjugated streptavidin for 20 min at room
temperature. Substrate solution (tetramethylbenzidine;
Sigma-Alrich) was added, incubation continued at
room temperature in the dark for 30 min, and the re-
action was stopped using H2SO4 (1 M). Absorbance
measurements were read at 450 nm using a Synergy
HT Multi-Mode Microplate Reader (Biotek, Winooski,
VT). Cytokine concentrations were calculated relative
to the appropriate standard curve and expressed as
pg cytokine/μg of protein. Nitric oxide (NO) release
was assayed using a Greiss reagent assay (Invitrogen;
G7921), per the manufacturer’s instructions. NO concen-
trations were calculated using standard curves generated
from a nitrite stock, and results were expressed in
micromoles.
IL-10 fluorescent in situ hybridization (FISH),
immunohistochemistry, and quantification of IL-10
co-localization
20 μm coronal brain sections were cut on a cryostat,
mounted on gelatin-coated glass slides (Superfrost Plus,
Fisher Scientific, Tusin, CA), and stored at −80 °C until
use. Fluorescent in situ hybridization (FISH) was
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performed as per the manufacturer’s instructions using
RNAscope® Technology 2.0 Red Fluorescent kit for Fresh
Frozen Tissue (Advanced Cell Diagnostics, Inc., Hay-
ward, CA). Tissue sections were dehydrated by 50, 70,
and 100% ethanol gradually for 5 min, and then boiled
for 3–5 min with pretreatment 2 solution, incubated
with pretreatment 3 solution, and incubated with target
IL-10 probe (Mus musculus interleukin 10 (IL-10)
mRNA; accession number NM_010548.2, target region
2–1095) at 40 °C for 2 h in the HybEZ humidified incu-
bator. A dapB probe targeting a bacterial gene was used
as a negative control and Ppib (Mus musculus peptidyl-
prolyl isomerase B mRNA; accession number
NM_011149.2, target region 98–856) was used as a posi-
tive control. After FISH, slides were washed three times
with PBS and blocking with PBS containing 0.5% Triton
X-100 and 2% normal goat serum for 1 h. Immunohisto-
chemistry was performed using polyclonal anti-rabbit
Iba-1 (1:500, Wako Chemicals, Richmond, VA) incu-
bated overnight at 4 °C. Alexa Fluor 488-conjugated goat
anti-rabbit IgG (1:1000, Invitrogen, Carlsbad, CA) was
applied for 1 h at room temperature. Sections were
rinsed with PBS three times and incubated in PBS with
DAPI solution (1:50.000) for counterstained nuclei. The
sections were washed three times in distilled water and
coverslipped with Fluoro-Gel with Tris Buffer mounting
medium (Electron Microscopy Sciences, Hatfield, PA).
Experiments were repeated three times.
All analyses were performed on digital images cap-
tured using a ×20 objective in a sampled region within
the ipsilateral primary somatosensory cortex with a field
of 151.894 mm2 around the impact site. Two to three
fields were randomly selected per brain section (see Fig 6
B1) between −1.70 and −2.30 mm from the bregma, and
a total of 2 to 4 brain sections per brain. Images were
taken in the cortical layers III–IV for sham mice. IL-10
positive cells (red) that colocalized with DAPI nuclei
(blue) were manually counted. The negative control
probe did not contain any stained cells. Stained cells
were examined under a florescent microscope (Axioplan
2 Zeiss) and were analyzed using Image J software
(http://rsbweb.nih.gov/ij/). RNA positive cells were
quantitated in each cortical sampling zone, each field of
view analyzed was the sum of three images of sequential
optical Z-stack images combined into a single overlay
image, and IL-10 positive cells were counted using the
overlay. The result from all the fields of view in a given
animal was averaged to obtain the value for that individ-
ual (n = 5/group). Double positive cells were identified
using the IL-10 probe and colocalization with Iba-1
(green) were based on analysis of microscopic fields of
view as previously described [30], keeping all acquisition
parameters constant. The percentage of mRNA IL-10
positive cells that colocalized with Iba-1 immunoreactive
cells relative to the total number of IL-10 positive cells
was assessed. A confocal microscope (Leica SP8) was
used to take images from FISH-ISH brain sections using
×20, ×40, and ×63 objectives.
Statistical analysis
Randomization protocols were employed in all experi-
ments, and individuals performing analysis were blinded to
treatment and genotype groups. Data are reported as the
mean ± SEM, and the number of experiments is indicated
in each case. Statistical analysis was carried out using a
two- or three-way analysis of variance (ANOVA) with post
hoc Bonferroni tests or one-way ANOVA followed by post
hoc Newman-Keuls analysis to identify specific differences
between groups. When comparisons were being made be-
tween two conditions, an unpaired Student’s t test was per-
formed. Significance level was set as P < 0.05.
Results
LPS/IL-4 induces a mixed phenotype in BMDMs
It is well documented that macrophages/microglia
adopt distinct phenotypes in response to inflamma-
tory stimuli such as LPS (pro-inflammatory) or IL-4
(anti-inflammatory) [31, 32], however, recently it has
been observed that after TBI, macrophages/microglia
express markers associated with both pro- and anti-
inflammatory phenotypes [12–14]. To mimic this acti-
vation spectrum in vitro, BMDMs were incubated in
the presence of both LPS (10 ng/ml) and IL-4
(10 ng/ml), and this combined treatment significantly
upregulated both pro- and anti-inflammatory activa-
tion markers. Specifically, LPS/IL-4 stimulation led to
a significant increase in the supernatant concentration
of TNFα (P < 0.001; Student’s t test; Fig. 1a) and IL-6
(P < 0.001; Student’s t test; Fig. 1b), both of which are
cytokines associated with a pro-inflammatory pheno-
type. We also observed elevated levels of nitrite (P <
0.001; Student’s t test; Fig. 1c), an indication of in-
creased NO production. The changes in pro-
inflammatory markers were also accompanied by an
increase in Arg1 protein (P < 0.001; Student’s t test;
Fig. 1d), and an upregulation in YM1 mRNA expres-
sion (P < 0.001; Student’s t test; Fig. 1f ), both markers
of anti-inflammatory macrophages. Of note, when we
stimulated BMDMs with only LPS or IL-4 alone,
there was increased expression of markers of pro-
and anti-inflammatory phenotypes, respectively, but
mixed pro- and anti-inflammatory phenotype markers
were not detected (data not shown). These results
demonstrate that LPS/IL-4 stimulation of BMDMs
produces a mixed pro- and anti-inflammatory activa-
tion state, similar to the activation profile observed in
the TBI brain.
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Fig. 1 LPS/IL-4 induces a mixed phenotype in BMDMs. (a-f) LPS/IL-4 (both 10 ng/ml; 24 h) stimulation significantly increased the production of TNFα (a), IL-6
(b), and Nitrite (b) in BMDMs from WT mice (***P< 0.001; Student’s t test). LPS/IL-4 increased Arg1 (d) protein expression (representative western immunoblot
shown (e)) and YM1 (f) mRNA expression in BMDMs (***P< 0.001; Student’s t test). All data are expressed as means (±SEM; n= 3)
Fig. 2 NOX2 deficiency alters macrophage response to LPS/IL-4. LPS/IL-4 (both 10 ng/ml; 24 h) stimulation significantly increased the release of TNFα
(a), IL-6 (b), and Nitrite (c) in WT and NOX2−/− BMDMs (***P < 0.001; ANOVA). LPS/IL-4-induced increase in pro-inflammatory markers was significantly
reduced in and NOX2−/− BMDMs compared with WT BMDMs (++P < 0.01, +++P < 0.001, WT LPS/IL-4 vs. NOX2−/− LPS/IL-4; ANOVA). LPS/IL-4
increased Arg1 (d) protein expression (representative western immunoblot shown (e)) and YM1 (f) mRNA expression in WT and NOX2−/− (***P <
0.001; ANOVA). Expression of anti-inflammatory markers was significantly increased in NOX2−/− BMDMs compared with WT BMDMs (++P < 0.01,
+++P < 0.001, WT LPS/IL-4 vs. NOX2−/− LPS/IL-4; ANOVA). LPS/IL-4 significantly decreased CD206 mRNA expression in WT BMDMs (*P < 0.05; ANOVA;
g), while CD206 mRNA expression was significantly increased in NOX2−/− BMDMs following LPS/IL-4 stimulation (+++P < 0.001, NOX2−/− con vs. NOX2
−/− LPS/IL-4; ANOVA). All data are expressed as means (±SEM; n = 6)
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NOX2 deficiency alters macrophage response to LPS/IL-4
Given that NOX2−/− TBI mice exhibit enhanced anti-
inflammatory activation that is associated with improved
outcomes following TBI [24], we set out to investigate
mechanisms of NOX2-dependent macrophage pheno-
type switching using the LPS/IL-4 stimulation model.
WT and NOX2−/− BMDMs were treated with LPS/IL-4
for 24 h, and pro and anti-inflammatory activation
markers were assessed. LPS/IL-4 significantly increased
supernatant concentration of TNFα (P < 0.001; ANOVA;
Fig. 2a), IL-6 (P < 0.001; ANOVA; Fig. 2b), and nitrite (P
< 0.001; ANOVA; Fig. 2c) in WT BMDMs. In contrast,
levels of each pro-inflammatory marker were signifi-
cantly reduced in LPS/IL-4 stimulated NOX2−/−
BMDMs (P < 0.05 [TNFα, IL-6]; P < 0.001 [nitrite];
ANOVA; Fig. 2a–c). In addition, LPS/IL-4 significantly
increased Arg1 protein (P < 0.001; ANOVA; Fig. 2d) and
YM1 mRNA (P < 0.001; ANOVA; Fig. 2f ) expression in
WT BMDMs; expression of both anti-inflammatory
markers were significantly increased beyond WT levels
in NOX2−/− cells (P < 0.01; ANOVA; Fig. 2d, f ). CD206
is another anti-inflammatory activation marker, and
LPS/IL-4 stimulation led to a significant decrease in
CD206 mRNA expression in WT BMDMs (P < 0.05;
ANOVA; Fig. 2g). In contrast, LPS/IL-4 significantly
increased CD206 mRNA expression in NOX2−/−
BMDMs (P < 0.001; ANOVA; Fig. 2g).
STAT1 activation is attenuated in NOX2−/− BMDMs,
whereas STAT6 activation is unchanged
Having observed genotype-related changes in the ex-
pression of markers associated with the pro- and anti-
inflammatory phenotypes, we set out to investigate
changes in signaling pathways involved in the induction
of these activation states. STAT1 is elevated following
stimulation with pro-inflammatory cytokines and/or
TLR agonists [5, 8]. Here, we demonstrate that STAT1
phosphorylation is significantly elevated in WT and
NOX2−/− BMDMs in response to LPS/IL-4 stimulation
(P < 0.001; ANOVA; Fig. 3a, c). However, STAT1 activa-
tion was significantly reduced in LPS/IL-4 treated NOX2
−/− cells when compared to WT cells (P < 0.05; ANOVA;
Fig. 3c). STAT6 is a part of the IL-4 signaling cascade
[6, 33] and having observed enhanced expression of
anti-inflammatory markers in NOX2−/− cells we antici-
pated that these changes were mediated by STAT6 activa-
tion. LPS/IL-4 stimulation significantly increased pSTAT6
expression in WT and NOX2−/− BMDMs (P < 0.001;
ANOVA; Fig. 3b, d), however, there was no genotype-
related difference in STAT6 activation.
IL-10 and STAT3 signaling are increased in LPS/IL-4
stimulated NOX2−/− BMDMs
We demonstrated that the LPS/IL-4-mediated increase
in anti-inflammatory markers in NOX2−/− BMDMs was
independent of STAT6 activation, therefore, we set out
to determine what signaling pathways were involved
in the NOX2-dependent shift towards an anti-inflammatory
phenotype. We next measured supernatant concentration of
IL-10 in LPS/IL-4-treated cells; there was a significant
increase in IL-10 production in WT and NOX2−/− BMDMs
(P < 0.001; ANOVA; Fig. 4a), and this effect was greater in
NOX2−/− cells when compared to WT cells (P < 0.001;
ANOVA; Fig. 4a). We also observed an increase in
Fig. 3 STAT1 activation is attenuated in NOX2−/− BMDMs, whereas STAT6 activation is unchanged. (a, b) Protein expression of phosphorylated
STAT1 and phosphorylated STAT6 in response to LPS/IL-4 stimulation was assessed by western immunoblotting. (c) LPS/IL-4 (both 10 ng/ml;
24 h) increased pSTAT1 expression (**P* < 0.001, ANOVA) in WT BMDMs. In contrast, LPS/IL-4-induced increase in pSTAT1 was significantly reduced
in NOX2−/− BMDMs (+P < 0.05, WT LPS/IL-4 vs. NOX2−/− LPS/IL-4; ANOVA). (d) LPS/IL-4 significantly increased pSTAT6 (***P < 0.001; ANOVA) in WT
and NOX2−/− BMDMs, but no genotype related differences were observed. All data are expressed as means (± SEM n = 5)
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STAT3 phosphorylation in WT and NOX2−/− cells
(P < 0.001; ANOVA; Fig. 4b, c). Notably, STAT3 activation
was significantly increased in LPS/IL-4 treated NOX2−/−
BMDMs when compared to WT BMDMs (P < 0.001;
ANOVA; Fig. 4c). We then analyzed the expression of
inflammatory markers downstream of IL-10 such as
IL-4Rα and SOCS3 [34]. Consistent with the activation of
IL-10 signaling there was a significant increase in IL-4Rα
(P < 0.001; ANOVA; Fig. 4d) and SOCS3 (P < 0.001;
ANOVA; Fig. 4e) mRNA expression in NOX2−/− BMDMs
when compared to levels in WT BMDMs.
Increased anti-inflammatory activation in NOX2−/−
BMDMs is mediated through IL-10
In order to test whether IL-10 mediates the anti-
inflammatory shift in NOX2−/− macrophages, WT and
NOX2−/− BMDMs were stimulated with LPS/IL-4 in
the presence or absence of neutralizing αIL-10. As
previously observed, LPS/IL-4 treatment significantly in-
creased STAT3 activation in WT BMDMs (P < 0.01;
ANOVA; Fig. 5a, b); an effect that was significantly in-
creased in NOX2−/− BMDMs (P < 0.05; ANOVA; Fig. 5b).
In the presence of αIL-10, pSTAT3 expression was sig-
nificantly reduced in NOX2−/− BMDMs (P < 0.001;
ANOVA; Fig. 5b), and the genotype effect was lost.
Analysis of STAT6 activation confirmed equal pSTAT6
expression in WT and NOX2−/− BMDMs following LPS/
IL-4 stimulation (P < 0.001; ANOVA; Fig. 5a, c). IL-10
neutralization significantly decreased STAT6 activation
in both genotypes (P < 0.01 [WT]; P < 0.001 [NOX2−/−];
ANOVA; Fig. 5c), but STAT6 activation remained sig-
nificantly elevated when compared to control unstimu-
lated cells. We next assessed Arg1 (Fig. 5a, d), IL-4Rα
(Fig. 5e), SOCS3 (Fig. 5f ), and IL-10 (Fig. 5g) expression
in this experimental paradigm, and as predicted, there
was a significant increase in each marker in NOX2−/−
BMDMs when compared to WT BMDMs (P < 0.05
[Arg1; SOCS3; IL-10]; P < 0.001 [IL-4Rα]; ANOVA;
Fig. 5d–g). In the presence of αIL-10, the genotype ef-
fects on Arg1 and IL-4Rα expression were lost, and
levels were returned to that of unstimulated cells (P <
0.001; ANOVA; Fig. 5d, e). LPS/IL-4-induced SOCS3
and IL-10 mRNA expression was increased in the pres-
ence of αIL-10 (P < 0.001, P < 0.01; ANOVA; Fig. 5f, g);
however, the genotype-related effect on SOCS3 was lost
when IL-10 was neutralized by αIL-10 (Fig. 5f ).
NOX2 deficiency results in increased cortical IL-10 expres-
sion following controlled cortical impact
Having demonstrated that IL-10/STAT3 signaling medi-
ates the genotype-related changes in anti-inflammatory
activation in NOX2−/− BMDMs, we then set out to
evaluate genotype related changes in IL-10 expression in
the TBI brain using a moderate-level CCI model. IL-10
mRNA expression was measured in ipsilateral cortex of
sham and TBI WT and NOX2−/− mice at 24 and 72 h
Fig. 4 IL-10 production and downstream effectors are elevated in NOX2−/− BMDMs in response to LPS/IL-4. (a) LPS/IL-4 (both 10 ng/ml; 24 h) stimulation
significantly increased IL-10 protein concentration in WT and NOX2−/− BMDMs (***P< 0.001; ANOVA). The LPS/IL-4-induced increase in IL-10 concentration
was significantly increased in NOX2−/− BMDMs compared with WT BMDMs (+++p < 0.001, WT LPS/IL-4 vs. NOX2−/− LPS/IL-4; ANOVA). (b, c) Protein expression
of phosphorylated STAT3 was significantly increased in WT and NOX2−/− BMDMs following LPS/IL-4 stimulation (***P< 0.001; ANOVA; representative western
immunoblot shown in b). LPS/IL-4-induced pSTAT3 expression was significantly increased in NOX2−/− BMDMs compared with WT BMDMs (+++P< 0.001, WT
LPS/IL-4 vs. NOX2−/− LPS/IL-4; ANOVA). (d) LPS/IL-4 significantly increased IL-4RαmRNA expression NOX2−/− BMDMs (***P< 0.001; ANOVA). (e) SOCS3 mRNA
expression was significantly increased in WT and NOX2−/− BMDMs following LPS/IL-4 stimulation (***P< 0.001; ANOVA). LPS/IL-4-induced SOCS3 expression
was significantly increased NOX2−/− BMDMs compared with WT BMDMs (+++P< 0.001, WT LPS/IL-4 vs. NOX2−/− LPS/IL-4; ANOVA). All data are expressed as
means (± SEM, n=6)
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and 7 days post-injury (Fig. 6a). IL-10 mRNA expression
was significantly increased in WT and NOX2−/− TBI
mice when compared to sham levels at all time points
examined. Notably, there was a significant increase in
IL-10 mRNA expression in NOX2−/− TBI mice at 72 h
and 7 days when compared to WT TBI mice (P < 0.05;
[72 h]; P < 0.01 [7 days]; ANOVA; Fig. 6a). To identify
the cellular source of IL-10, we combined IL-10 mRNA
Fig. 5 Increased anti-inflammatory activation in NOX2−/− BMDMs is mediated through IL-10. (a) Representative immunoblots for pSTAT3, STAT3, Arg1, pSTAT6,
STAT6, and β-actin. (b) LPS/IL-4 (both 10 ng/ml; 24 h) increased the expression of pSTAT3 in WT BMDMs (*P<0.05, vs. control; ANOVA), and LPS/IL-4-induced
pSTAT3 expression was significantly increased in NOX2−/− BMDMs (++P<0.01, WT LPS/IL-4 vs. NOX2−/− LPS/IL-4; ANOVA). Co-incubation of BMDMs with neutral-
izing anti-IL-10 (αIL-10) attenuated the LPS/IL-4-induced increase in pSTAT3 in NOX2−/− BMDMs (^^^P<0.001, NOX2-/- LPS/IL-4 vs. NOX2-/- LPS/IL-4 +αIL-10;
ANOVA). (c) αIL-10 attenuated the LPS/IL-4-induced increase pSTAT6 expression (***P<0.001, control vs. LPS/IL-4; ##P<0.01, WT LPS/IL-4 vs. WT LPS/IL-4 + αIL-10;
^^^P<0.001, NOX2−/− LPS/IL-4 vs. NOX2−/− LPS/IL-4 +αIL-10; ANOVA), and no genotype-related changes were observed. (d, e) LPS/IL-4 induced an increase in
Arg1 (d) protein expression, and IL-4Rα (e) mRNA expression in WT and NOX2−/− BMDMs (***P<0.001, vs. control; ANOVA); these effects were significantly in-
creased in NOX2−/− BMDMs (+P<0.05, +++P<0.001, WT LPS/IL-4 vs. NOX2−/− LPS/IL-4; ANOVA). The LPS/IL-4 mediated effects on Arg1 and IL-4Rα expression
were significantly reduced in the presence of αIL-10 (^^^p< 0.001, NOX2−/− LPS/IL-4 vs. NOX2−/− LPS/IL-4; ###p< 0.001, WT LPS/IL-4 vs. WT LPS/IL-4 +αIL-10;
ANOVA). (f, g) SOCS3 and IL-10 mRNA expression was significantly increased in WT and NOX2−/− BMDMs following LPS/IL-4 stimulation (*P<0.05, ***P< 0.001,
vs. control; ANOVA); the LPS/IL-4 effect was significantly increased in NOX2−/− BMDMs compared with WT BMDMs (*P< 0.05, WT LPS/IL-4 vs. NOX2−/− LPS/IL-4;
ANOVA). SOCS3 and IL-10 expression levels were significantly increased in the presence of αIL-10 (^^P < 0.01, ^^^P < 0.001, NOX2−/− LPS/IL-4 vs.
NOX2−/− LPS/IL-4 + αIL-10; ###P < 0.001, WT LPS/IL-4 vs. WT LPS/IL-4 + αIL-10; ANOVA). All data are expressed as means (± SEM, n = 6)
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FISH with immunohistochemical markers for macro-
phages/microglia in the ipsilateral cortex of WT and
NOX2−/− sham and TBI mice at 7 days post-injury.
There was a significant increase in IL-10-positive cells in
the cortex of NOX2−/− TBI mice when compared to WT
TBI mice (P < 0.05; ANOVA; Fig. 6b), and approximately
78% of the IL-10-positive cells were Iba-1-positive mac-
rophages/microglia (representative images Fig. 6c–h).
Together, these data indicate that NOX2 deficiency re-
sults in a significant increase in IL-10 expression in
macrophages/microglia during the acute-subacute phase
following TBI.
Increased anti-inflammatory marker expression in the
cortex of NOX2−/− TBI mice is associated with enhanced
IL-10/STAT3 signaling
IL-10 expression was enhanced in NOX2−/− TBI mice
compared to WT TBI mice; therefore, we next assessed
STAT3 and STAT6 signaling pathways and anti-
inflammatory marker expression at 72 h post-injury. TBI
Fig. 6 IL-10 is increased in the cortex of NOX2−/− TBI mice. (A) IL-10 mRNA expression was assessed in the ipsilateral cortex of WT and NOX2−/− sham
and TBI mice at 24, and 72 h and 7 days post-injury. TBI increased IL-10 mRNA at all time points (**P< 0.01, [24 h], ***P< 0.001 [72 h], vs. sham; ANOVA). IL-10
expression was significantly increased in NOX2−/− TBI mice at 72 h and 7 days (+P < 0.05, ++\P < 0.01, WT TBI vs. NOX2−/− TBI; ANOVA). All data are
expressed as means (± SEM, n=5). (B) Quantification of IL-10 mRNA positive cells in the ipsilateral cortex of WT and NOX2−/− sham and TBI mice at
7 days post-injury. TBI increased IL-10 expression when compared to sham (***P < 0.001; ANOVA), and this effect was significantly greater in NOX2−/−
TBI mice (+P < 0.05, WT TBI vs. NOX2−/− TBI; ANOVA). All data are expressed as means (± SEM, n = 5). (B1) Schematic representation of the injured
coronal brain section, the red squares indicate the fields that were examined in this study. (C–H) Representative images from the ipsilateral cortex of
WT (C–D2) and NOX2−/− (E–F2) TBI mice at 7 days post-injury. Images show reduced IL-10 positive cells (red) in the injured cortex of WT TBI (C, inset
in D) compared to NOX2−/− TBI mice (E, inset in F). IL-10 was predominantly expressed in microglia/macrophages detected by immunohistochemistry
(Iba-1, green) and nuclei (dapi, blue) in both groups; WT (C1–C2, insets in D–D2) and in NOX2−/− TBI mice (E1–E2, insets in F2–F3). A white striped line
delineates the cavity and the perilesional cortex (C–C2 and E–E2). (G) Table illustrating quantification analysis of %IL-10/Iba-1+ cells in the ipsilateral
cortex of WT and NOX2−/− sham and TBI mice. (H) High magnification (inset circle in D–D2) of a representative image for IL-10 positive (h1) microglia/
macrophage (h2–h3, Iba-1 in green, dapi in blue) showing cytoplasmic and perinuclear IL-10 mRNA expression with puncta spike that represents a
single IL-10 mRNA transcript (white arrowheads in h1). Scale bars 75 μm for C–C2 and E–E2; F2; 50 μm D–D2, F–F2; and 20 μm for h1–h3
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significantly increased the expression of pSTAT3 in the
ipsilateral cortex of both WT and NOX2−/− mice
(P < 0.001; ANOVA; Fig. 7b). Notably, STAT3 activation
was robustly and significantly increased in NOX2−/− TBI
mice when compared to WT TBI mice (P < 0.05;
ANOVA; Fig. 7b). STAT6 activation was increased in
WT and NOX2−/− TBI mice (P < 0.01; ANOVA; Fig. 7c);
however, there was no genotype-related change in
pSTAT6 expression. In addition, TBI resulted in a
significant increase in the cortical expression of IL-4Rα
(P < 0.001; ANOVA; Fig. 7d), SOCS3 (P < 0.001;
ANOVA; Fig. 7e), TGFβ (P < 0.001; ANOVA; Fig. 7f ),
SHIP1 (P < 0.001; ANOVA; Fig. 7g), Arg1 (P < 0.001;
ANOVA; Fig. 7h), and YM1 (P < 0.01; ANOVA; Fig. 7i)
mRNA in WT and NOX2−/− TBI mice. The injury effect
on inflammatory markers downstream of IL-10 was
significantly increased in the ipsilateral cortex of NOX2−/−
TBI mice when compared to WT TBI mice (P < 0.05
[IL-4Rα; SOCS3; Arg1; YM1]; P < 0.001 [SHIP1; TGFβ];
ANOVA; Fig. 7d–i; also Additional file 1: Table S1).
IL-10 promotes an anti-inflammatory environment in
NOX2−/− mice following TBI
Finally, to determine if IL-10 promotes the anti-
inflammatory response in NOX2−/− TBI mice, we blocked
IL-10 in the brain using the IL-10 neutralization strategy
that we employed in prior BMDM studies. To achieve this,
WT mice and NOX2−/− TBI mice had an i.c.v. osmotic
pump implanted on the contralateral side to infuse neu-
tralizing αIL-10 (1 mg/ml) or equal concentration isotype
control αIgG (αIgG2b K) into the lateral ventricle for 72 h,
after which ipsilateral cortex tissue was collected to assess
anti-inflammatory markers (Fig. 8a). TBI increased the ex-
pression of IL-4Rα (P < 0.001; ANOVA; Fig. 8b), SOCS3
(P < 0.001; ANOVA; Fig. 8c), TGFβ (P < 0.001; ANOVA;
Fig. 8d), YM1 (P < 0.001; ANOVA; Fig. 8e), and Arg1
Fig. 7 Increased expression of anti-inflammatory markers in the cortex of NOX2−/− TBI mice is associated with enhanced IL-10/STAT3 signaling. (a) Protein
expression of phosphorylated STAT3 and phosphorylated STAT6 was assessed by western immunoblotting in the ipsilateral cortex of WT and NOX2−/−
sham and TBI mice at 72 h post-injury. (b) pSTAT3 expression was significantly increased in WT and NOX2−/− TBI mice (***P< 0.001, vs. sham; ANOVA).
pSTAT3 expression was significantly increased in the cortex of NOX2−/− TBI mice when compared to WT TBI mice (+P< 0.05, WT TBI vs. NOX2−/− TBI;
ANOVA). (c) TBI significantly increased pSTAT6 expression in the cortex of WT and NOX2−/− mice (***P< 0.001, vs. sham; ANOVA); there was no
genotype-related differences in pSTAT6 expression following TBI. (d-i) TBI significantly increased IL-4Rα (d), SOCS3 (e), TGFβ (f), SHIP1 (g), Arg1 (h), and YM1
(i) mRNA expression in the ipsilateral cortex of WT and NOX2−/−mice at 72 h post-injury (***P< 0.001, vs. sham; ANOVA). The expression of each anti-
inflammatory marker was significantly increased in NOX2−/− TBI mice when compared to WT TBI mice (+P< 0.05, ++P< 0.01, WT TBI vs. NOX2−/− TBI;
ANOVA; d-i). All data are expressed as means (±SEM; n= 5)
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(P < 0.05; ANOVA; Fig. 8f) mRNA in all TBI mice com-
pared to WT sham mice. As predicted, the effect of TBI on
IL-4Rα, SOCS3, TGFβ, and YM1 was significantly
increased in NOX2−/− TBI mice compared to WT TBI
mice (P < 0.05 [YM1]; P < 0.01 [IL-4Rα; TGFβ]; P < 0.001
[SOCS3]; ANOVA; Fig. 8b–e). Notably, the NOX2
−/−-dependent upregulation of anti-inflammatory markers
after TBI was significantly reduced when IL-10 was neu-
tralized using αIL-10, such that the αIL-10-treated NOX2
−/− TBI group returned to αIgG-treated WT TBI levels
(P < 0.05 [YM1]; P < 0.01 [IL-4Rα; SOCS3; TGFβ];
ANOVA; Fig. 8b–e).
Discussion
Redox signaling regulates macrophage responses during in-
flammation [16], and NOX2/ROS are implicated in second-
ary neuroinflammatory cascades in ischemic brain injury
[35, 36], spinal cord injury (SCI) [37, 38], and TBI [21, 23,
26]. NOX2 is highly expressed in macrophage/microglia up
to 12 months after moderate-to-severe TBI [21], and inhib-
ition of NOX2 is neuroprotective and reduces
inflammatory-mediated neuronal cell death after TBI [23–
26]. We recently reported that NOX2 inhibition also en-
hances anti-inflammatory activation of macrophage/micro-
glia following TBI [24]. Thus, NOX2 may act as a critical
switch between pro- and anti-inflammatory phenotypes
after TBI. Similar findings in SCI [37, 39] and stroke [40]
models indicate that this may be a common cellular mech-
anism that regulates CNS injury responses. Therefore, the
goal of the present study was to investigate signaling path-
ways that regulate NOX2-dependent phenotypic changes in
macrophages and relate these signaling events back to TBI.
To this end, we developed an in vitro model of macrophage
activation that mimics characteristic features of the mixed
pro- and anti-inflammatory phenotypes observed in the
TBI brain [12–14], and used it to identify IL-10-STAT3 sig-
naling as a key mechanism by which NOX2 inhibition reg-
ulates macrophage activation states after TBI.
Fig. 8 IL-10 promotes an anti-inflammatory environment in cortex of NOX2−/− TBI mice. (a) Neutralizing anti-IL-10 (αIL-10; 1 mg/ml, i.c.v.) or con-
trol αIgG2b K was administered to WT or NOX2−/− TBI mice for 72 h, and ipsilateral cortex tissue was collected for mRNA analysis. (b-f) TBI in-
creased IL-4Rα (b), SOCS3 (c), TGFβ (d), YM1 (e), and Arg1 (f) mRNA expression in the ipsilateral cortex of WT and NOX2−/−mice (***P < 0.001, vs.
sham; ANOVA). TBI effect on anti-inflammatory marker expression was significantly increased in NOX2−/− TBI mice when compared to WT TBI mice
(+P < 0.05, ++P < 0.01, +++P < 0.001, WT αIgG2b K TBI vs. NOX2−/− αIgG2b K TBI; ANOVA). αIL-10 treatment significantly reduced the expression of
all anti-inflammatory markers in NOX2−/− TBI mice (#P < 0.05, ##P < 0.01, NOX2−/− αIgG2b K TBI vs. NOX2−/− αIL-10 TBI; ANOVA). All data are
expressed as means (±SEM; n = 6)
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Whereas many previous studies have demonstrated
that macrophages/microglia in vitro can be stimulated to
adopt specific phenotypes, it appears less likely that such
defined phenotypes exist in vivo [9]. We, and others,
have demonstrated that following brain trauma macro-
phages/microglia adopt mixed phenotypes and express
both pro and anti-inflammatory activation markers
[12–14]. Here, we demonstrated that similar to the
activation profile in the TBI brain, macrophages stimu-
lated with combined LPS/IL-4, but not LPS or IL-4
alone, upregulated mixed phenotypic markers associated
with both pro- and anti-inflammatory activation states.
When we compared the responses of WT and NOX2−/−
BMDMs to the mixed LPS/IL-4 stimulation model,
we found that NOX2 deficiency was associated with
decreased production of pro-inflammatory mediators.
This activation profile is consistent with prior studies in
NOX2−/− microglia exposed to LPS challenge [27, 41].
There was also a significant increase in anti-inflammatory
activation markers in NOX2−/− BMDMs. These findings
are significant because there are increased numbers of
anti-inflammatory microglia/macrophages in the injured
cortex of NOX2−/− TBI mice [24]. Of note, it was not pos-
sible to promote this NOX2-dependent phenotype shift
when BMDMs were treated with only pro-inflammatory
stimuli (LPS or IFNγ alone; data not shown) or anti-
inflammatory stimuli (IL-4 alone; data not shown),
highlighting the importance of mixed environmental stim-
uli (combined LPS/IL-4) for NOX2-dependent macro-
phage phenotype responses. In the context of TBI, it is
intriguing to speculate on the significance of these
stimulus-driven effects such that they highlight intrinsic
tension between activation pathways. Similar to responses
in wound healing macrophages [42], coincident pro- and
anti-inflammatory activation may be an attempt to
fine-tune the injury response in which the two path-
ways support each other to facilitate neuroprotection
and immune resolution that may be important for
neurorestoration after TBI, thereby revealing their
complementary nature. However, complete absence of
a molecular signaling cascade (activation by only pro-
(LPS) or anti-inflammatory (IL-4) stimuli in BMDMs)
or the loss of molecular signaling over time (domin-
ant NOX2 response after TBI [12]) may significantly
impact the functional effects of the opposite micro-
glial/macrophage activation state.
We investigated the impact of NOX2 deficiency on
signaling cascades involved in regulating macrophage
phenotypes, with particular emphasis on mechanisms
that drive anti-inflammatory activation that may be rele-
vant for neuroprotection and neurorestoration following
TBI. The role of STAT1 in the induction of the pro-
inflammatory phenotype is well-established [43], and
STAT1 is required for LPS-induced gene expression in
macrophages [5]. In our model, the mixed LPS/IL-4
stimulus significantly increased pSTAT1 expression in
WT and NOX2−/− BMDMs, but STAT1 activation was
significantly reduced in NOX2−/− BMDMs. This is in
agreement with a previous report where NOX deficient
macrophages incubated in the presence of IFNγ/LPS
exhibited decreased STAT1 activation [44]. In addition,
previous work demonstrated that LPS-induced IFNβ is
required for STAT1 activation [45], and this may be a
mechanism that explains reduced pSTAT1 and de-
creased pro-inflammatory marker expression in NOX2
−/− BMDMs.
IL-4 stimulation increases the expression of markers
associated with the anti-inflammatory phenotype, and
STAT6 activation appears to be essential for driving
these changes [6]. Our recent study suggested that the
enhanced anti-inflammatory environment in the cortex
of NOX2−/− TBI mice is mediated, at least in part, by
IL-4Rα-positive infiltrating macrophages [24]. Here, we
demonstrated that LPS/IL-4 treatment increased anti-
inflammatory markers in NOX2−/− BMDMs when
compared to WT BMDMs. Unexpectedly, we observed
no genotype-related change in STAT6 activation, which
conflicts with a prior report showing that pSTAT6
expression is enhanced in NOX2−/− BMDMs [44].
Such discrepancies may be due to the different activa-
tion stimuli employed in each study. Nevertheless, the
results from the current study suggest that enhanced
anti-inflammatory changes in NOX2−/− BMDMs are
not mediated by increased STAT6 signaling.
Having established that anti-inflammatory responses
in NOX2−/− BMDMs were not due to enhanced
STAT6 activation, we then identified an alternative
pathway that could mediate these effects. IL-10 is a
pleiotropic immunoregulatory cytokine that plays a
critical role in controlling inflammation and immune
responses [46]. IL-10 regulates TLR signaling [47],
and IL-10 deficient mice exhibit exaggerated re-
sponses to LPS [48]. IL-10 can also enhance anti-
inflammatory activation induced by IL-4 [7]. Here, we
show that LPS/IL-4 stimulation enhances IL-10 re-
lease, an effect which is robustly increased in NOX2
−/− BMDMs. These data are consistent with a recent
report showing that ROS inhibition using a mitochon-
drial complex 1 inhibitor decreases LPS-induced acti-
vation of macrophages and increases IL-10 production
[49]. IL-10 mediates its effects through activation of
STAT3 [50], and in the current study we found that
STAT3 signaling was significantly increased in NOX2−/−
BMDMs. Stimulation of macrophages with IL-10 leads to
the upregulation of several genes, including IL-4Rα and
SOCS3 [34], and in response to LPS/IL-4, mRNA expres-
sion of both markers was significantly increased in NOX2
−/− compared to WT BMDMs.
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To investigate whether IL-10 plays a critical role in the
NOX2-dependent phenotype switch, WT and NOX2−/−
BMDMs were stimulated with LPS/IL-4 in the presence
or absence of a neutralizing αIL-10 antibody. Increased
pSTAT3 expression in NOX2−/− BMDMs was attenuated
in the presence of αIL-10, demonstrating that the
genotype-related effect on STAT3 activation was medi-
ated by IL-10. IL-4-stimulated macrophage activation
can be synergized by IL-10 [7], and when IL-10 was
neutralized, there was a significant reduction in IL-4Rα
and Arg1. Interestingly, when IL-10 was neutralized, the
LPS/IL-4 effects on SOCS3 and IL-10 were further
increased; significantly, the NOX2 genotype-related
effects were abolished with αIL-10 treatment. These
observations are consistent with the fact that TLR4
activation induces SOCS3 and IL-10 expression [32, 51];
by removing the inhibitory effect of IL-10, LPS-induced
changes are increased. Together, these data demonstrate
that in the absence of NOX2, there is increased IL-10/
STAT3 signaling, which in turn results in enhanced anti-
inflammatory macrophage activation.
Clinically, IL-10 is upregulated during the acute phase
after moderate-to-severe TBI [52, 53], and several pre-
clinical studies report neuroprotective effects of IL-10
treatment in acute brain injury that can be attributed to
its anti-inflammatory activities [54–56]. IL-10 treatment
produces strong neuroprotective effects in LPS-induced
dopaminergic neurotoxicity models [57], and these ef-
fects are mediated by inhibition of microglial activation
and NOX2-dependent ROS in neuron-glia co-cultures.
In the present study, we demonstrated that IL-10
expression was increased in the ipsilateral cortex of WT
and NOX2−/− TBI mice, and that this effect was signifi-
cantly greater in NOX2−/− animals. Importantly, our in
situ analysis showed that IL-10 expression was robustly
upregulated in approximately 78% of macrophages/
microglia within the injured cortex of NOX2−/− TBI
mice. We previously identified the peak of macrophage
infiltration after TBI to be at 72 h post-injury [12], and
this is the same time point at which IL-10 expression is
maximal in WT mice. There was also increased pSTAT3
expression, but no change in STAT6 activation, in TBI
NOX2−/− mice at 72 h post-injury, suggesting that the
changes observed were as a result of increased STAT3
activity. STAT3 activation has been described in second-
ary injury responses following TBI and SCI [58–60].
Fig. 9 Schematic of NOX2 regulation of macrophage activation. Activation of TLR4 initiates a signaling cascade that leads to activation of NOX2
and increased ROS production; this in turn induces the activation of STAT1, which leads to an increase in the production of pro-inflammatory
mediators. TLR4 signaling also induces the production of IL-10, which acts in autocrine fashion to regulate TLR4-induced changes. In NOX2−/−
cells, TLR4-induced changes are significantly different; NOX2-deficiency is associated with a decrease in pro-inflammatory markers and significantly
greater IL-10 production. This increase in IL-10 leads to a robust increase in STAT3 signaling, which in conjunction with STAT6 activation, leads to
increased expression of anti-inflammatory markers
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Although some studies have suggested a beneficial role
[59], others have reported that STAT3 activation is
detrimental [61]. These conflicting reports highlight the
complexity of STAT3 activation in secondary injury and
differential STAT3 cellular responses during acute CNS
injury (STAT3 effects in glia vs. neurons). Here, we
clearly demonstrate that NOX2 deficiency resulted in
increased STAT3 activation in macrophages (BMDMs),
and that a similar STAT3 activation profile was observed
in the injured cortex of NOX2−/− TBI mice. In addition
to enhanced STAT3 signaling, several genes downstream
of IL-10 (IL-4Rα, TGFβ, SOCS3, SHIP1) and other
anti-inflammatory genes (Arg1 and YM1) were robustly
upregulated in the injured cortex of NOX2−/− TBI mice.
Therefore, despite no differences in IL-4-mediated
signaling, our data indicate that the anti-inflammatory
response in NOX2−/− TBI mice may be as a result of
enhanced IL-10/STAT3 signaling.
Finally, to address whether IL-10 is essential for the en-
hanced anti-inflammatory environment in NOX2−/− TBI
mice, we used a neutralizing antibody to inhibit IL-10 within
the CNS as previously described [29]. After IL-10
neutralization, the TBI-induced increase in expression of
anti-inflammatory markers in NOX2−/− TBI mice was sig-
nificantly reduced compared to expression levels in IgG
control NOX2−/− TBI mice. These results indicate that IL-
10 is a major contributor to the anti-inflammatory environ-
ment in the injured cortex of NOX2−/− TBI mice. When
combined with our recent report [24], these studies indicate
that NOX2 inhibition in macrophages switches them to-
wards an anti-inflammatory phenotype through an IL-10/
STAT3 dependent pathway, which may contribute to the
neuroprotective effects that result in long-term neurological
recovery after TBI. Interestingly, following SCI infiltrating
monocyte-derived macrophages that display an immunoreg-
ulatory phenotype with high IL-10 expression play a critical
role in controlling the inflammatory response within the le-
sion microenvironment, which in turn is associated with
improved motor function recovery [62]. Furthermore,
adoptive transfer of anti-inflammatory macrophages that
infiltrate the lesion site after SCI where they produce
high levels of IL-10 and IL-13 to promote axon
remyelination and preserve neuronal function [63].
Conclusions
These studies demonstrate that in response to mixed
inflammatory stimuli BMDMs from NOX2−/− mice
exhibit decreased pro-inflammatory activation, and a
concomitant increase in anti-inflammatory activation,
and that this switch is IL-10/STAT3-dependent (Fig. 9).
Furthermore, our in vivo TBI studies indicate that NOX2
deficiency drives an anti-inflammatory response in the in-
jured cortex that is mediated by IL-10. Overall, these find-
ings indicate that interventions that inhibit NOX2 activity
in macrophages/microglia may improve outcomes follow-
ing TBI not only by limiting pro-inflammatory and neuro-
toxic responses, but also by enhancing IL-10-mediated
responses that are neuroprotective.
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